Phase 2 Clinical Study to Evaluate the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Gel Form Applied to Women With Sexual Arousal Disorder
Latest Information Update: 24 Oct 2024
Price :
$35 *
At a glance
- Drugs BZ 371A (Primary)
- Indications Sexual function disorders
- Focus Therapeutic Use
- Sponsors Biozeus
- 22 Oct 2024 Planned End Date changed from 1 Dec 2024 to 31 Mar 2025.
- 22 Oct 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Feb 2025.
- 22 Oct 2024 Status changed from not yet recruiting to recruiting.